# Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

> **NCT06096870** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (estimated)

## Conditions studied

- Prostate Cancer
- Recurrent Prostate Cancer
- PET Positive

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** PDS01ADC

## Key facts

- **NCT ID:** NCT06096870
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06096870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06096870, "Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06096870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*